The Foundation for Innovative New Diagnostics (FIND) announced last Friday that it has awarded grants to a number of companies to address the urgent diagnostic needs for hepatitis C virus (HCV). These grants will be used to conduct feasibility studies of various technologies that could transform HCV testing at the point of care. Mologic is among the companies receiving support to develop and validate prototype HCV core antigen (cAg) tests on their innovative rapid diagnostic test platform. Read more on the official website: https://www.finddx.org/news/find-announces-new-wave-activities-addressing-challenges-threatening-hepc-elimination/
Mologic is a leading developer of lateral flow and rapid diagnostic technologies, products and services. We work with companies, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-care.
Our Co-founder and Chief Scientific Officer, Paul Davis, was the originator of the Clearblue pregnancy test. Launched in 1988, it was the world’s first commercial application of lateral flow technology. The creativity, insight and knowledge that led to that ground-breaking invention has guided Mologic since our formation in 2003.